FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Method and device for female urinary incontinence

Date/App# patent app List of recent Receptor-related patents
07/10/14
20140194599
 Anti-human interleukin-20 antibodies patent thumbnailAnti-human interleukin-20 antibodies
Anti-human il20 monoclonal antibodies that can reduce il20 mediated activation of both il20r1/il20r2 and il22r1/il20r2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders..
07/10/14
20140194597
 Modified chimeric polypeptides with improved pharmacokinetic properties patent thumbnailModified chimeric polypeptides with improved pharmacokinetic properties
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
07/10/14
20140194595
 Method and composition for crystallizing g protein-coupled receptors patent thumbnailMethod and composition for crystallizing g protein-coupled receptors
Certain embodiments provide a method for crystallizing a gpcr. The method may employ a fusion protein comprising: a) a first portion of a g-protein coupled receptor (gpcr), where the first portion comprises the tm1, tm2, tm3, tm4 and tm5 regions of the gpcr; b) a stable, folded protein insertion; and c) a second portion of the gpcr, where the second portion comprises the tm6 and tm7 regions of the gpcr..
07/10/14
20140194550
 Method and device for female urinary incontinence patent thumbnailMethod and device for female urinary incontinence
A method and device for use in stress female urinary incontinence. A small, flexible adhesive patch is applied directly to the clitoris of a person suffering from stress female urinary incontinence.
07/10/14
20140194515
 Use of a composition comprising an antacid, a mucolytic and a gelling agent in the treatment of cold patent thumbnailUse of a composition comprising an antacid, a mucolytic and a gelling agent in the treatment of cold
The present invention is directed to a medicine to alleviate and cure colds by reducing acid content and stimulation of increased mucus production due to the fact that active components of the substance consist of acid stanching components like proton pumps stanches, histamine-2-receptor-antagonists, mucus stimulating components as acetylcysteine and alginic acid. This together creates an optimal healing environment in the respirator passages..
07/10/14
20140194472
 Vitamin d receptor-coregulator inhibitors patent thumbnailVitamin d receptor-coregulator inhibitors
Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin d receptor target gene, inhibiting interactions between the vitamin d receptor and at least one vitamin d receptor coactivator, for treating cancer in a subject, and for inhibiting angiogenesis in a subject.. .
07/10/14
20140194471
 Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors patent thumbnailSubstituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors
In one aspect, the invention relates to substituted 1-benzylindolin-2-one analog compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/10/14
20140194468
 Compounds that suppress cancer cells and exhibit antitumor activity patent thumbnailCompounds that suppress cancer cells and exhibit antitumor activity
The present invention provides compounds s3i-201.1066 (formula 1) and s3i-201.2096 (formula 2) as selective stat3 binding agents that block stat3 association with cognate receptor ptyr motifs, stat3 phosphorylation and nuclear translocation, stat3 transcriptional function, and consequently induced stat3-specific antitumor cell effects in vitro and antitumor response in vivo.. .
07/10/14
20140194462
 Alpha-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof patent thumbnailAlpha-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
The present application is related to compounds represented by formula i, which are novel allosteric modulators of α7nachr. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nachr in a mammal by administering an effective amount of a compound of formula i..
07/10/14
20140194437
 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor patent thumbnailAcylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor
R5 is an oxygen containing radical such as c1-c2-alkoxy-c1-c4-alkyl, fluorinated c1-c2-alkoxy-c1-c4-alkyl, hydroxy-c1-c4-alkyl, fluorinated hydroxy-c1-c4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, c3-c5 cycloalkyl, fluorinated c3-c5 cycloalkyl, c3-c5 cycloalkoxy-c1-c4-alkyl and fluorinated c3-c5 cycloalkoxy-c1-c4-alkyl.. .
07/10/14
20140194435
Novel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/10/14
20140194434
Novel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/10/14
20140194433
Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
The invention relates to novel modulators of the cold menthol receptor trpm8, to a method for modulating the trpm8 receptor using said modulators; to the use of the modulators for induction of cold sensation; and to objects and means produced using said modulators.. .
07/10/14
20140194426
Dual-acting oxazole antihypertensive agents
Wherein: ar, z, r3, r4 and r5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.
07/10/14
20140194414
Tetracyclic compounds
This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles.
07/10/14
20140194411
Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds.
07/10/14
20140194409
Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
The present invention relates to 4-((1r,3s)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine d1 and d2 receptors as well as the serotonin 5ht2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime.. .
07/10/14
20140194404
Amidopyrazole inhibitors of interleukin receptor-associated kinases
This invention relates to amidopyrazole compounds that are inhibitors of interleukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.. .
07/10/14
20140194355
Isolated nucleic acid molecules encoding variant activin receptor polypeptides
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
07/10/14
20140194295
Method of measuring adaptive immunity
A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it.
07/10/14
20140193899
Monoclonal antibodies to fibroblast growth factor receptor 2
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
07/10/14
20140193523
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one nk-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug.
07/10/14
20140193459
Vaccine composition containing synthetic adjuvant
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
07/10/14
20140193439
Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
Compositions, recombinant vaccines and live alternated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes il-15ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed..
07/10/14
20140193425
Treatment of cancer with alk1 antagonists
Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (alk1) antagonist are provided. Methods for selecting a subject for treatment with an alk1 antagonist based on the subject being identified as responsive to such treatment are also provided.
07/10/14
20140193418
Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human epo receptor, wherein the antibody binds to epo receptor fragment lpgpggsvdiv (seq id no: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kd.. .
07/10/14
20140193411
Multimeric constructs
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
07/10/14
20140193409
Fusion proteins for delivery of gdnf to the cns
The invention provides compositions, methods, and kits for increasing transport of gdnf across the blood brain barrier while allowing its activity to remain substantially intact. The gdnf is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems..
07/10/14
20140193402
Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
07/10/14
20140193398
Polymalic acid-based nanobiopolymer compositions
Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-l-malic acid) pmla covalently linked to molecular modules that include morpholino antisense oligonucleotides (aona), an sirna or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described..
07/10/14
20140193396
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
07/10/14
20140193393
Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist
Methods of using an etb receptor agonist, such as irl-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The etb receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident..
07/10/14
20140193376
Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (hscs) from the bone marrow to the peripheral blood are disclosed.
07/10/14
20140193364
Tam receptor ligands, metabolites and precursors thereof in the detection and modulation of inflammatory neuropathological disease
The present disclosure relates to the use of tam receptor ligands, metabolites, precursor and binding partners thereof in the field of inflammatory neuropathology. This includes the early diagnosis and monitoring of an inflammatory neuropathology as well as screening for medicaments used in the treatment and prophylaxis of such a condition.
07/10/14
20140193334
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, c1-6alkylene-phenyl-nh—c(o)—r15, folic acid, αvβ3 integrin rgd binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein r15 is a peptide..
07/10/14
20140193311
Integrated high throughput system for the analysis of biomolecules
Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules..
07/10/14
20140193185
Image forming apparatus, and image forming method
An image forming apparatus is provided. The image forming apparatus includes a photoreceptor; a charger to charge a surface of the photoreceptor; a circulating agent applicator to apply a circulating agent to the surface of the photoreceptor while contacting the surface of the photoreceptor to form a film of the circulating agent on the surface of the photoreceptor; and a contact member contacted with the surface of the photoreceptor.
07/10/14
20140192131
Image forming device
An image forming device includes a photoreceptor drum including a target surface that is scanned in a main scanning direction and a sub-scanning direction, an exposure head including a plurality of light emitting segments aligned in parallel to the main scanning direction, an exposure driving unit which selectively drives the plural light emitting segments, a storing unit which stores a profile where the respective positions of the plural light emitting segments correspond to a correction amount from the main scanning direction toward the sub-scanning direction at every position, and a correcting unit which smoothes a local change of the correction amount in the profile.. .
07/10/14
20140192122
Image forming apparatus
An image forming apparatus including: a photoreceptor; a charger configured to charge a photoreceptor surface; an optical scanning device configured to expose the photoreceptor surface to form an electrostatic latent image thereon; a developing device configured to develop the electrostatic latent image to form a toner image thereon; a transfer member configured to transfer the toner image to a sheet; a fixing device configured to fix the toner image thereon; and a control unit configured to carry out exposure amount control for formation of an image having a pattern with a spatial frequency from 0.1 c/mm to 3.0 c/mm so that after the exposure, there will be an electric potential difference v1 between an edge portion and a non-edge portion of the pattern and so that there will be an electric potential difference v2 larger than v1 between an edge-surrounding portion and the other portions of a non-image area.. .
07/10/14
20140191630
Current diverter ring
The current diverter rings and bearing isolators serve to dissipate an electrical charge from a rotating piece of equipment to ground, such as from a motor shaft to a motor housing. One embodiment of the current diverter ring includes an inner body and an outer body configured to clamp at least one conductive segment between them.
07/03/14
20140188495
Method for assessing and managing health risks associated with heavy metal pollution
A method for assessing and managing health risks of heavy metal pollution. The method includes: 1) investigation and analysis of environmental pollution; 2) population exposure analysis; 3) risk assessment and representation; 4) risk perception and estimate of acceptable level of risk; 5) identification of an overall boundary of risk management; 6) identification of priority pollutants; and 7) identification of a key population and a key managing point.
07/03/14
20140187758
Methods for purifying insect membrane-bound receptor proteins from recombinant production hosts
The invention is drawn to a method for purifying membrane-bound proteins expressed in recombinant insect cells using n-laurosarcosine. The invention is particularly suited for expressing cadherin-type receptors cloned from ostrinia nubilalis, european corn borer, and expressed in sf9 insect cells.
07/03/14
20140187752
Antigenic compositions and use of same in the targeted delivery of nucleic acids
Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized, for example by receptor-mediated endocytosis.
07/03/14
20140187645
Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure
This disclosure concerns the discovery of (r,r)- and (r,s)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided.
07/03/14
20140187641
Estrogen receptor ligands and methods of use thereof
The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (crpc), metastatic castration resistant prostate cancer (mcrpc), and methods of reducing high or increasing psa levels and/or increasing shbg levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (crpc) and metastatic castration resistant prostate cancer (mcrpc). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to adt and reduce high or increasing psa levels.
07/03/14
20140187600
Use of metabotropic glutamate receptors
The invention concerns the use an mglur modulator, e.g. An mglur5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction..
07/03/14
20140187585
5-ht2b receptor antagonists
The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-ht2b receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.. .
07/03/14
20140187581
Heteroaryl compounds as 5-ht4 receptor ligands
The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (i) are useful in the treatment of various disorders that are related to 5-ht4 receptors..
07/03/14
20140187573
Substituted morphinans and the use thereof
And pharmaceutically acceptable salts and solvates thereof, wherein r1, r2, r3, r4a, and r4b are defined as set forth in the specification. The invention is also directed to use of compounds of formula i to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.
07/03/14
20140187571
7,8-cyclicmorphinan analogs
And pharmaceutically acceptable salts and solvates thereof, wherein cy, r1a-r3a, r4a, and r4b are defined as set forth in the specification. The invention is also directed to use of compounds of formula i-a to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.
07/03/14
20140187563
Combination therapy in treatment of oncological and fibrotic diseases
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (vegfrs) in conjunction with a thrombin inhibitor.. .
07/03/14
20140187559
Inhibitors of the fibroblast growth factor receptor
Described herein are inhibitors of fgfr, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.. .
07/03/14
20140187557
Benzocycloheptane and benzoxepine derivatives
The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the ghs1a-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof..
07/03/14
20140187554
Modulators of the nuclear hormone receptor ror
The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as rorα, rorβ, or rorγ. Compounds of the invention can be effective modulators at concentrations ineffective to act on lxr receptors, or on other nuclear receptors, or other biological targets.
07/03/14
20140187550
Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
R1, r3, qa, qb and q are as defined herein, for the treatment of a disease mediated by the s1p2 or s1p3 receptor, such as inflammatory or obstructive airways disease.. .
07/03/14
20140187549
Pyridonemorphinan analogs and biological activity on opioid receptors
And pharmaceutically acceptable salts and solvates thereof, wherein , r1a, r3a, r4, y and za are defined as set forth in the specification. The invention is also directed to use of compounds of formula i-a to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.
07/03/14
20140187536
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
Methods for reducing toxicity or side effects caused by administration of a rycal compound for repairing ryanodine receptor channel leaks when treating a disorder in a subject caused by such leaks. These methods are based upon the selection for administration of those rycal compounds having properties including an ec50 value of 102 nm when assayed for its ability to facilitate the rebinding of fkbp12.6 to pka-phosphorylated ryr2 or less and less than 50% inhibition of the herg k+ channel (ikr) when administered at 10 μm to reduce compound toxicity or side effects after administration compared to other rycal compounds not having those properties..
07/03/14
20140187520
Stable injectable pharmaceutical composition of vitamin d receptor agonist and process for preparation thereof
The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a vitamin d receptor agonist, particularly paricalcitol, and a process of preparation thereof.. .
07/03/14
20140187516
Dosage regimen of an s1p receptor modulator
S1p receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.. .
07/03/14
20140187507
Treatment of parkinsons disease with glycolipids
This invention provides compounds, compositions, and methods for treating parkinson's disease. In particular, there is provided gm1 ganglioside analogs that are capable of penetrating the blood brain barrier and entering the cytoplasm of neurons.
07/03/14
20140187504
Prevention and treatment of inflammatory conditions
The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ald). More specifically the present embodiments relate to the prevention and treatment of ald through the administration of an retinoic acid receptor (rar) agonist.
07/03/14
20140187485
Novel receptor nucleic acids and polypeptides
Disclosed are nucleic acids encoding baff-r polypeptides, as well as antibodies to baff-r polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided..
07/03/14
20140187484
Na/k-atpase-derived peptide src inhibitors and ouabain antagonists and uses thereof
A novel src inhibitor that targets the na/k-atpase/src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.. .
07/03/14
20140187470
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cgmp-dependent phosphodieasterases.. .
07/03/14
20140187437
Cross-reactive sensor arrays and methods of use
Disclosed herein are methods and compositions directed to the construction of aptamer-based receptors and cross-reactive sensor arrays of such receptors and the use of the same in disease detection and management.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5112

3354

2 - 1 - 74